Eli Lilly's $1,350 Analyst Target Misses the Real Test: Can Yesterday's Guidance Hold?

Jefferies' $1,350 Target Raises the Bar, but Lilly Already Raised Its Own

Jefferies raising its price target to $1,350 gets the attention, but it is not the real test. Lilly already raised the bar on itself, moving full-year revenue guidance to $85 billion to $87 billion and, after it had raised its annual profit forecast earlier this year, landing on an updated range of $35.50 to $36.50.

That changes the standard. The stock is no longer being asked to imagine a big future; it is being asked to support the numbers management just put behind public confidence.

But a higher guide also leaves less room for error. If demand softens even modestly, investors are likely to focus less on future pipeline upside and more on whether the latest quarter can clear the new standard.

Lilly's Q2 Demand Story Was Strong, but the Earnings Picture Got Cloudier

Revenue and profit both strengthened

Q2 looked like a genuine demand story, not a one-off accounting bump. Revenue rose 48% to $23.0 billion, driven mainly by Mounjaro and Zepbound volume. Reported EPS reached $7.94, and non-GAAP EPS reached $8.38. That supports the case that current sales momentum is real.

The acquired IPR&D charge changes how investors should read guidance

The catch is that reported and non-GAAP EPS also included $3.03 of acquired IPR&D charges, versus $0.14 a year earlier. Lilly said that charge more than offset the benefit of its raised underlying non-GAAP EPS guidance, leaving the reported full-year range at $35.50 to $36.50.

That does not break the business case, but it does mean the guidance lift should not be read too cleanly. Acquired IPR&D is a pipeline investment cost, not evidence that core drug demand weakened. The better test is whether sales strength is improving enough to absorb heavier R&D spending.

Pipeline progress still helps support the story

Lilly is also getting support from a backlog of late-stage assets. Investors had reacted strongly to compelling new data for retatrutide, and the company has already pursued U.S. FDA submission for orforglipron for type 2 diabetes. That helps explain why expectations remain high even after management raised the near-term bar.

What the Market Needs to See Next

Much of the good news may already be priced in

A recent report noted Lilly shares were $200 below the $1,350 target, which shows the stock still has upside in some analysts' view. At the same time, it is not a deep-value setup waiting to be discovered. Analyst optimism and price-target changes are tailwinds, not proof.

The next month should shift the debate from estimates to execution

The next catalyst window should bring more than headline risk. Lilly said it expects to launch its oral weight-loss pill later this year, and investors have already responded to compelling new data for retatrutide. If those advances strengthen the franchise, the current guidance may look manageable.

Competition, however, is getting sharper. Reuters reported that oral Wegovy remains stronger than analysts initially expected. If oral treatments gain share quickly, Lilly may have to prove that its lead is durable, not just temporary.

What would move the stock from here

What would reinforce the bull case - Management continues to raise expectations rather than merely defend them - Mounjaro and Zepbound demand keep strengthening - Oral product timelines stay on track - Pipeline updates keep the franchise conversation alive beyond the current leaders

What would weaken the story - Guidance holds on paper, but execution gets messy - Oral competitors take more share than expected - Pipeline excitement fails to translate into a durable second wave of revenue

The real test is no longer whether an analyst likes the stock. It is whether Lilly can turn yesterday's guidance into another quarter of clean execution.